Evidence map›Paper›PMID 23707781›Full record

ArticleCancer cell2013

SDH mutations establish a hypermethylator phenotype in paraganglioma.

Eric Letouzé, Cosimo Martinelli, Céline Loriot, Nelly Burnichon, Nasséra Abermil, Chris Ottolenghi, Maxime Janin, Mélanie Menara, An Thach Nguyen, Paule Benit and 8 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cancer cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02672020 (The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card), which is not on this map. Cited by 441 papers.

0numbers the graph read from it
0cells of the map it votes in
441citing papers in PubMed
59.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02672020 nacompletednot on this mapstarted 2015, after this paper: background citation

The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2015 to 2019Enrolled448ConditionsAdrenal Gland NeoplasmsArmsomics identity card
3 · Its place in the literature

Who cites it

441 citing papers in PubMed, 760 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Pilot study: transduction of primary paraganglioma chromaffin tumour cells with inducible c-MYC drives cell proliferation.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Article

381 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Eric LetouzéProgramme Cartes d'Identité des Tumeurs, Ligue Nationale Contre Le Cancer, 75013 Paris, France.
Cosimo Martinelli
Céline Loriot
Nelly Burnichon
Nasséra Abermil
Chris Ottolenghi
Maxime Janin
Mélanie Menara
An Thach Nguyen
Paule Benit
Alexandre Buffet
Charles Marcaillou
Jérôme Bertherat
Laurence Amar
Pierre Rustin
Aurélien De Reyniès
Anne-Paule Gimenez-Roqueplo
Judith Favier
Délégation Paris 5 · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FRLa Ligue Contre le Cancer · FRHôpital Robert-Debré · FRIntegraGen (France) · FRParis Cardiovascular Research Center · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paragangliomas are neuroendocrine tumors frequently associated with mutations in RET, NF1, VHL, and succinate dehydrogenase (SDHx) genes. Methylome analysis of a large paraganglioma cohort identified three stable clusters, associated with distinct clinical features and mutational status. SDHx-related tumors displayed a hypermethylator phenotype, associated with downregulation of key genes involved in neuroendocrine differentiation. Succinate accumulation in SDH-deficient mouse chromaffin cells led to DNA hypermethylation by inhibition of 2-OG-dependent histone and DNA demethylases and established a migratory phenotype reversed by decitabine treatment. Epigenetic silencing was particularly severe in SDHB-mutated tumors, potentially explaining their malignancy. Finally, inactivating FH mutations were identified in the only hypermethylated tumor without SDHx mutations. These findings emphasize the interplay between the Krebs cycle, epigenomic changes, and cancer.

Indexed as

DNA MethylationAdolescentAdultAgedAged, 80 and overAnimalsCell MovementChildChromaffin CellsColorectal NeoplasmsEpigenesis, GeneticFemaleGene Knockout TechniquesGene SilencingGlioblastomaHistonesHistonesSuccinate Dehydrogenase

Identifiers

PMID23707781
OpenAlexW2061662711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.